New pill hopes to tackle tough lymphoma

NCT ID NCT07283796

Recruiting now Disease control Sponsor: Haisco Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental oral drug, HSK47977, in 110 adults with relapsed or refractory Non-Hodgkin's lymphoma. The study has two parts: first, finding the safest dose, then expanding to see how well it works. Participants must have measurable tumors and adequate organ function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HSK47977 tablets
What this could lead to: If successful, this could point toward a new oral treatment option for people with Non-Hodgkin's lymphoma that has not responded to other therapies.
What could go wrong: This is an early Phase 1 trial with only 110 participants, focused on safety and dosing. It is too soon to know if the drug will work, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NHL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NHL

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chinese Academy of Medical Sciences Blood Diseases Hospital
RECRUITING

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.